The EASL Mentorships Programme was created as a means of enhancing scientific exchange and personal developmental relationships in which a more experienced and knowledgeable hepatologist would guide a young investigator through a crucial stage of their career path.
About EASL Mentorships
The programme is not simply about answering ad hoc questions or providing occasional help, it is about establishing an ongoing relationship (continuous learning, dialogue, and challenge).
Mentoring is a process that involves communication and is relationship based, it is a process enabling the informal transmission of knowledge and a means of support for the mentee that is relevant to work, career, and professional development.
EASL Mentorships 2019 Mentors
Professor Dr. Thomas Berg completed his medical training at the Universities of Tübingen, Freiburg and Berlin, Germany. He specialized in internal medicine in 2001 and in Gastroenterology and Hepatology in 2007 at the University Medicine Berlin, and became a lecturer in this subject in 2002.
In 2002, Professor Berg took up the position of Associate Director and Professor of Medicine at the Department of Hepatology and Gastroenterology of Charité, Campus Virchow-Clinic, University Medicine in Berlin, where he was Head of the Liver Out-Patient Clinic and the Laboratory for Molecular Hepatitis and Viral Diagnostics. Since December 2009, he has been the Head of the Section of Hepatology at the University Hospital in Leipzig, and since April 2020 Head of the Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Germany. He is Chair of the University Liver Tumor Center, and Vice-Chair of the University Liver Transplant Center Leipzig.
His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials.
He is Secretary General of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019. He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 350 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 74 (Scopus).
Maurizia R. Brunetto is Adjunct Professor of Internal Medicine at the University Pisa and Director of the Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital. She received a 2-year (1982-1983) fellowship from the National Foundation of Cancer Research of Bethesda to study the role of aldehyde metabolites and lipid peroxidation in liver damage, and 1 year (1993-1994) fellowship from the Human Science Foundation of Japan to study of hepatitis viruses heterogeneity.
In 1989 she received the Young Investigator Award for the discovery of the HBeAg-defective HBV mutant from the European Association for the study of the Liver (EASL), and in 2007 the Young Investigator Award»of the Asian Pacific Association for the Study of the Liver (APSL) for the study of HBsAg serum levels kinetics during antiviral treatment in HBeAg negative chronic hepatitis B.
Her research activity has been mainly focused on the study of the pathogenetic implications of hepatitis virus (HBV, HCV and HDV) infection on the analysis of factors influencing the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma and on the treatment optimization of chronic viral hepatitis. She did seminal work in the clinic-pathologic characterization of the HBeAg negative form of chronic hepatitis B and its natural history and response to antiviral therapy.
Google Scholar Citation Report (Aug 2018)